Cargando…
Identification of myxobacteria-derived HIV inhibitors by a high-throughput two-step infectivity assay
BACKGROUND: Drug-resistance and therapy failure due to drug-drug interactions are the main challenges in current treatment against Human Immunodeficiency Virus (HIV) infection. As such, there is a continuous need for the development of new and more potent anti-HIV drugs. Here we established a high-t...
Autores principales: | Martinez, Javier P, Hinkelmann, Bettina, Fleta-Soriano, Eric, Steinmetz, Heinrich, Jansen, Rolf, Diez, Juana, Frank, Ronald, Sasse, Florenz, Meyerhans, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3852058/ https://www.ncbi.nlm.nih.gov/pubmed/24063434 http://dx.doi.org/10.1186/1475-2859-12-85 |
Ejemplares similares
-
Myxobacteria: natural pharmaceutical factories
por: Diez, Juana, et al.
Publicado: (2012) -
The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway
por: Fleta-Soriano, Eric, et al.
Publicado: (2014) -
Investigations on the mode of action of gephyronic acid, an inhibitor of eukaryotic protein translation from myxobacteria
por: Muthukumar, Yazh, et al.
Publicado: (2018) -
Correlating chemical diversity with taxonomic distance for discovery of natural products in myxobacteria
por: Hoffmann, Thomas, et al.
Publicado: (2018) -
Archazolid and apicularen: Novel specific V-ATPase inhibitors
por: Huss, Markus, et al.
Publicado: (2005)